# A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study

> **NCT00432679** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 149 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Rosiglitazone (BRL49653C)

## Key facts

- **NCT ID:** NCT00432679
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05-24
- **Primary completion:** 2007-03-28
- **Final completion:** 2007-03-28
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2022-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00432679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00432679, "A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00432679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*